Antibiotics can Increase the Risk of Crohn’s Disease

Antibiotic use is one factor associated with IBD risk in younger people, but it is unclear whether this association holds in older people.

To dig deeper, the researchers examined national medical data from 2000 to 2018 for Danish citizens aged 10 and above who had not been diagnosed with IBD.
They were particularly interested in learning whether the time and dose of antibiotics were relevant in the development of IBD and whether this varied by IBD and antibiotic type (2^✔ ✔Trusted Source
Antibiotic use as a risk factor for inflammatory bowel disease across the ages: a population-based cohort study

Go to source).

The survey comprised approximately 6.1 million people, with women accounting for slightly more than half of the participants. Between 2000 and 2018, 5.5 million people (91%) were prescribed at least one course of antibiotics.
Approximately 36,017 new instances of ulcerative colitis and 16,881 new cases of Crohn’s disease were diagnosed during this period.

Overall, usage of these medicines was associated with a greater risk of developing IBD, regardless of age, as compared to no use. However, older age was associated with the greatest risk.

Those aged between 10-40 years were 28% more likely to be diagnosed with IBD, those aged between 40-60 years were 48% more probable, and those over 60 years were 47% more likely.

Crohn’s disease had a somewhat greater risk than ulcerative colitis: 40% among 10- to 40-year-olds, 62% among 40- to 60-year-olds, and 51% among those over 60.
The danger appeared to be cumulative, with each consecutive course increasing the risk by 11%, 15%, and 14%, respectively, depending on the age band.

The biggest risk was reported among individuals prescribed five or more courses of antibiotics: a 69% increase in risk for 10- to 40-year-olds, a doubling in risk for 40- to 60-year-olds, and a 95% increase in risk for those over 60.

The timing appeared to be important as well, with the largest risk for IBD occurring 1-2 years following antibiotic exposure and each subsequent year associated with a decrease in risk.

IBD risk was 40% greater 1-2 years after using antibiotics among 10- to 40-year-olds, compared to 13% 4-5 years later. The similar figures for 40- to 60-year-olds were 66% vs. 21% and 63% vs. 22% for those over 60.

In terms of antibiotic class, nitroimidazoles and fluoroquinolones, which are commonly used to treat gut infections, were associated with the highest risk of IBD. Broad-spectrum antibiotics are so named because they target all bacteria, not just those that cause disease.

Nitrofurantoin was the only antibiotic that was not linked to an increased risk of IBD at any age.

Narrow-spectrum penicillin have also been linked to IBD, albeit to a lesser degree. This lends credence to the idea that alterations in the gut microbiome may play an important role and that many medications can alter the composition of microorganisms in the gut.

Because this is an observational study, the cause cannot be determined. The researchers also remark that there is no information available on what the medications were for or how many of the patients consumed them.

However, they provide some reasonable scientific explanations for the findings, noting the natural decline in both the resilience and diversity of microorganisms in the gut microbiome associated with age, which antibiotic use is expected to exacerbate.
“Furthermore, with repeated courses of antibiotics, these shifts can become more pronounced, ultimately limiting recovery of the intestinal microbiota,” they add.
Limiting prescriptions for antibiotics may not only help to curb antibiotic resistance but may also help lower the risk of IBD, they venture.

“The association between antibiotic exposure and the development of IBD underscores the importance of antibiotic stewardship as a public health measure, and suggests the gastrointestinal microbiome as an important factor in the development of IBD, particularly among older adults,” they conclude.

Antibiotics: A Boon or Bane for Crohn’s Disease Patients?

Research suggests that too much bacteria in the small intestine may be common in people with IBS. Antibiotics, which kill bacteria, may help bring the bacterial balance closer to normal.

These medicines may:

• 
  
  Reduce the dangers of harmful gut bacteria.
• Help protect the intestinal lining from bacterial infection.
• Lower inflammation is the body’s attack against bacteria and viruses.
• Preserve healthy bacteria in the colon.

References :

1. Antibiotics, gut microbiota, and irritable bowel syndrome: What are the relations? – (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968486/)
2. Antibiotic use as a risk factor for inflammatory bowel disease across the ages: a population-based cohort study – (https://gut.bmj.com/content/early/2023/01/03/gutjnl-2022-327845)

Source: Medindia